FindTrial
Sign In

Study on the Role and Molecular Mechanism of HKDC1 in Regulating PD - L1 - Mediated Renal Cancer Immune Evasion by Activating STAT1 in Tumor Cells

Study on the Role and Molecular Mechanism of HKDC1 in Regulating PD - L1 - Mediated Renal Cancer Immune Evasion by Activating STAT1 in Tumor Cells

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600116467
Enrollment
Unknown
Registered
2026-01-09
Start date
2026-01-15
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Cell Carcinoma

Interventions

Observation group:N/A

Sponsors

The First Hospital of Jiaxing
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Informed consent shall be obtained from the patient or their legal representative. 2. Histopathologically confirmed as renal cell carcinoma.

Exclusion criteria

Exclusion criteria: 1. History of malignancies in other organs, infectious diseases, autoimmune diseases, or other relevant conditions. 2. Patients with renal cell carcinoma who have previously received clinical interventions such as surgery, radiofrequency ablation, immunotherapy, high-intensity focused ultrasound, cryoablation, small-molecule targeted therapy (e.g., Sunitinib), radiotherapy, or chemotherapy. 3. Non-primary renal cell carcinoma.

Design outcomes

Primary

MeasureTime frame
Protein expression levels:HKDC1, STAT1, and PD-L1;—

Countries

China

Contacts

Public ContactYifang Cao

The First Hospital of Jiaxing

15868303311@qq.com+86 573 8251 9776

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026